BioWorld

Dec. 20, 2005

View Archived Issues

Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin

A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent Monday. (BioWorld Today) Read More

Palatin Stops NeutroSpec Sales To Investigate Reported Deaths

Read More

Hypnion Extending Series B: $20M More For Phase II Bid

Read More

FDA Now Has sBLA For Avastin In Relapsed Colorectal Cancer

Read More

Other News To Note

Read More

ICAAC Roundup

Read More